Comparing the current results to its competitors, 60 Degrees Pharmaceuticals Inc reported Revenue increase in the 2 quarter 2026 by 106.04 % year on year. The sales growth was above 60 Degrees Pharmaceuticals Inc 's competitors' average revenue growth of 0.13 %, achieved in the same quarter.
Due to outstanding performance in Overall company, revenue grew by 106.04 % 60 Degrees Pharmaceuticals Inc improved its market share, to approximately 0 %.
January 8, 2025
In a groundbreaking initiative set to enhance the treatment landscape for persistent babesiosis, 60 Degrees Pharmaceuticals has announced the enrollment of its first patient in a clinical study evaluating tafenoquine. This investigational oral medication, historically utilized for malaria prophylaxis and treatment, is now being studied for its potential to address persistent and relapsing infections caused by Babesia microti , a tick-borne parasite that can lead to severe complications in vulnerable populations.Babesiosis has emerged as a significant public health concern, particularly in regions where tick populations are abundant. The disease, often characterized by symptoms including fever, chills, and f...
May 30, 2024
In an exciting move towards combating the tick-borne disease babesiosis, 60 Degrees Pharmaceuticals (60P) will commence the first-ever clinical trial of tafenoquine at Tufts Medical Center. With enrollment set to begin on June 13, 2024, this groundbreaking study aims to evaluate the effectiveness and safety of tafenoquine in treating patients suffering from this debilitating condition. Additionally, 60P has received commendable feedback from the U.S. Food and Drug Administration (FDA) regarding the tafenoquine-babesiosis clinical trial protocol, indicating no material changes are required. Moreover, the company has also ventured into researching the efficacy of tafenoquine in treating canine babesiosis, a ti...
May 20, 2024
Exploring the Link Between Babesia Infections and Chronic Fatigue Syndrome: A New Study Funded by 60 Degrees PharmaceuticalsChronic Fatigue Syndrome (CFS), also known as myalgic encephalomyelitis (ME), remains one of the most enigmatic and debilitating conditions in modern medicine, affecting millions worldwide with its profound and persistent fatigue, cognitive difficulties, and array of other symptoms. Despite extensive research, the etiology of CFS largely eludes scientists. However, a recent initiative may illuminate a potential contributor: Babesia spp infections.In a significant stride towards unraveling the mystery of CFS, 60 Degrees Pharmaceuticals has generously funded a groundbreaking study at Nor...
February 20, 2024
In a significant move towards advancing global healthcare, 60 Degrees Pharmaceuticals has recently announced its sponsorship of pre-clinical studies on the potential use of tafenoquine in combating Candida spp infections, specifically Candida auris. This latest development adds to the company s diverse range of research initiatives, which also include investigating tafenoquine s efficacy in treating babesiosis, a tick-borne disease. With IRB approval obtained for a Phase IIA study, 60 Degrees Pharmaceuticals continues to solidify its position as a pioneering force in finding innovative solutions for these challenging medical conditions.Main The first groundbreaking announcement by 60 Degrees Pharmaceuticals ...
Publicly Traded Peers of 60 Degrees Pharmaceuticals Inc
Bristol myers Squibb Company Share Performance
+17.03%
This Quarter
Bristol myers Squibb Company
Profile
Bristol Myers Squibb Company operates a research and development-driven business model, focusing on the discovery and delivery of innovative medicines for various diseases. It emphasizes collaboration with academic institutions, government entities, and other pharmaceutical firms to enhance its therapeutic portfolio and improve patient outcomes.
Immunome Inc is a biotechnology company that focuses on developing novel immunotherapies. Their business model revolves around leveraging their proprietary discovery engine to identify therapeutic antibodies for infectious diseases and cancer. By collaborating with partners and through their own clinical development efforts, they aim to bring these promising treatments to the market.
Mineralys Therapeutics Inc is a biotechnology company that follows the business model of developing and commercializing novel therapeutics for various diseases. They focus on discovering and advancing small molecule drugs based on innovative research approaches. Their business model is centered around conducting preclinical and clinical trials, obtaining regulatory approvals, and ultimately bringing their therapeutic products to market for improved patient outcomes.
Sources:
60 Degrees Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on 60 Degrees Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
